Boxing heavyweight legend Mike Tyson has stepped into the spotlight again—this time as a cannabis entrepreneur. After meeting with former President Donald Trump, Tyson visited a Drug Enforcement Administration (DEA) laboratory to tour its facilities and promote his Tyson 2.0 cannabis brand.
Tyson’s brand, which he co-founded, offers a range of premium cannabis products including flower, vapes, edibles, and concentrates. Known for advocating plant medicine, Tyson aims to push industry standards and support cannabis reform. His DEA lab visit provided a rare glimpse at federal drug analysis processes and reinforced his commitment to transparency and scientific understanding.
The event raised eyebrows for its timing and symbolism—Tyson’s public alliance with both a Trump meetup and DEA officials plays into broader efforts to bridge gaps between cannabis advocates, law enforcement, and conservative figures. By engaging with both sides, Tyson signals that high-profile cannabis influencers can appeal across political divides.
Tyson used the visit to spotlight his business goals and social impact efforts, including plant medicine education and expungement advocacy. He emphasized that Tyson 2.0 is about more than profit—it’s about changing perceptions and pushing the legal boundaries of cannabis in America.
Industry analysts say Tyson’s tour could help shift public discourse, offering a visual of cannabis entrepreneurs engaging directly with federal institutions. While skeptics might question the optics, others see it as the kind of bold move that advances normalization and reform.
Whether this sparks real policy change remains to be seen. But Tyson’s strategy is clear: use celebrity clout to open doors—politically, scientifically, and culturally—and keep the cannabis conversation moving forward.
For more on topics like these, check this link out LATEST INDUSTRY NEWS
